Ruoqi Zhou

Ruoqi Zhou

Auto-generated profile, based on publicly available information

Ruoqi Zhou

The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Hepatology
Verified
Journal Article
Closed access
YSYu Shi
Yu Shi
RZRuoqi Zhou
Ruoqi Zhou
Seung Up KimSeung Up Kim
Seung Up Kim
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
ETEmmanuel Tsochatzis
Emmanuel Tsochatzis
OGon behalf of the VCTE-Prognosis Study Group
on behalf of the VCTE-Prognosis Study Group
Background and Aims: Weight control remains the cornerstone for metabolic dysfunction–associated steatotic liver disease (MASLD) management. We assessed the relationships between dynamic weight change and the risk of liver-related events (LREs) and liver stiffness changes in MASLD. Approach and Results: By enrolling adult MASLD individuals with ≥2 weight measurements from 16 tertiary referral centers, we assessed how longitude weight change, including the following categories (stable ≤5% change, weight loss >5% decrease, weight gain >5% increase) and changing status of obesity (persistent non-obesity, persistent obesity, transition from non-obesity to obesity, transition from obesity to non-obesity), were associated with LREs. Analyses were undertaken with multivariable linear regressions, Cox proportional hazards regression, and logistic regression, adjusting for age, sex, ethnicity, baseline BMI, hypertension, T2D, LSM, CAP, and SGLT-2i/GLP-1RAs usage. Analyses between weight change and liver stiffness change were also undertaken. A total of 10,014 MASLD individuals with ≥2 weight measurements were included. Over a measurement interval of 29.2 months, 123 LREs occurred during 12.4 months of follow-up after the final weight assessment. Weight gain >5% was associated with increased risk of LREs [aHR=1.84 (95% CI: 1.01–3.09), p =0.020] and liver stiffness progression [aOR=2.07 (95% CI: 1.55–2.74), p 5% exhibited liver stiffness improvement. Although those who progressed to or persisted with obesity had a higher LREs risk, obesity reversal had a comparable LREs risk [aHR=1.44 (95% CI: 0.57–3.61), p =0.435] to the persistent non-obese. Conclusions: In MASLD, weight gain is associated with increased LREs risks and liver stiffness progression. Conversely, weight loss confers benefits for liver stiffness improvement and modifies LREs risk in those who achieve obesity reversal.

15 July 2026 in Liver International
Verified
Journal Article
Closed access
PDF file
XZXiao-Dong Zhou
Xiao-Dong Zhou
RFRen Cheng-Han Fan
Ren Cheng-Han Fan
JCJian-Dong Chen
Jian-Dong Chen
XZXiqiao Zhou
Xiqiao Zhou
QTQian Tong
Qian Tong
TCthe CHAIN Consortium
the CHAIN Consortium

11 November 2025 in Hepatology
Verified
Journal Article
Closed access
YSYu Shi
Yu Shi
RZRuoqi Zhou
Ruoqi Zhou
YPYuanjie Pang
Yuanjie Pang
VWVincent Wai-Sun Wong
Vincent Wai-Sun Wong
MZMing-Hua Zheng
Ming-Hua Zheng

18 June 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RZRuoqi Zhou
Ruoqi Zhou
YSYu Shi
Yu Shi
XZXinrong Zhang
Xinrong Zhang
Click on the article title to read more.